16 research outputs found
Value of biomarkers in osteoarthritis: Current status and perspectives
Osteoarthritis affects the whole joint structure with progressive changes in cartilage, menisci, ligaments and subchondral bone, and synovial inflammation. Biomarkers are being developed to quantify joint remodelling and disease progression. This article was prepared following a working meeting of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis convened to discuss the value of biochemical markers of matrix metabolism in drug development in osteoarthritis. The best candidates are generally molecules or molecular fragments present in cartilage, bone or synovium and may be specific to one type of joint tissue or common to them all. Many currently investigated biomarkers are associated with collagen metabolism in cartilage or bone, or aggrecan metabolism in cartilage. Other biomarkers are related to non-collagenous proteins, inflammation and/or fibrosis. Biomarkers in osteoarthritis can be categorised using the burden of disease, investigative, prognostic, efficacy of intervention, diagnostic and safety classification. There are a number of promising candidates, notably urinary C-terminal telopeptide of collagen type II and serum cartilage oligomeric protein, although none is sufficiently discriminating to differentiate between individual patients and controls (diagnostic) or between patients with different disease severities (burden of disease), predict prognosis in individuals with or without osteoarthritis (prognostic) or perform so consistently that it could function as a surrogate outcome in clinical trials (efficacy of intervention). Future avenues for research include exploration of underlying mechanisms of disease and development of new biomarkers; technological development; the ‘omics’ (genomics, metabolomics, proteomics and lipidomics); design of aggregate scores combining a panel of biomarkers and/or imaging markers into single diagnostic algorithms; and investigation into the relationship between biomarkers and prognosis. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial
A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
Background: General recommendations for a reference case for economic studies in rheumatic diseases were published in 2002 in an initiative to improve the comparability of cost-effectiveness studies in the field. Since then, economic evaluations in osteoarthritis (OA) continue to show considerable heterogeneity in methodological approach. Objectives: To develop a reference case specific for economic studies in OA, including the standard optimal care, with which to judge new pharmacologic and non-pharmacologic interventions. Methods: Four subgroups of an ESCEO expert working group on economic assessments (13 experts representing diverse aspects of clinical research and/or economic evaluations) were charged with producing lists of recommendations that would potentially improve the comparability of economic analyses in OA: outcome measures, comparators, costs and methodology. These proposals were discussed and refined during a face-to-face meeting in 2013. They are presented here in the format of the recommendations of the recently published Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, so that an initiative on economic analysis methodology might be consolidated with an initiative on reporting standards. Results: Overall, three distinct reference cases are proposed, one for each hand, knee and hip OA; with diagnostic variations in the first two, giving rise to different treatment options: interphalangeal or thumb-based disease for hand OA and the presence or absence of joint malalignment for knee OA. A set of management strategies is proposed, which should be further evaluated to help establish a consensus on the "standard optimal care" in each proposed reference case. The recommendations on outcome measures, cost itemisation and methodological approaches are also provided. Conclusions: The ESCEO group proposes a set of disease-specific recommendations on the conduct and reporting of economic evaluations in OA that could help the standardisation and comparability of studies that evaluate therapeutic strategies of OA in terms of costs and effectiveness
Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
PURPOSE: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a considerable social and economic burden. Potential treatments are under development but, as yet, no guidelines support regulatory studies for new drugs to manage sarcopenia. The objective of this position paper is therefore to suggest a set of potential endpoints and target population definitions to stimulate debate and progress within the medico-scientific and regulatory communities. METHODS: A multidisciplinary expert working group was hosted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, which reviewed and discussed the recent literature from a perspective of clinical experience and guideline development. Relevant parallels were drawn from the development of definition of osteoporosis as a disease and clinical assessment of pharmaceutical treatments for that indication. RESULTS: A case-finding decision tree is briefly reviewed with a discussion of recent prevalence estimations of different relevant threshold values. The selection criteria for patients in regulatory studies are discussed according to the aims of the investigation (sarcopenia prevention or treatment) and the stage of project development. The possible endpoints of such studies are reviewed and a plea is made for the establishment of a core outcome set to be used in all clinical trials of sarcopenia. CONCLUSIONS: The current lack of guidelines for the assessment of new therapeutic treatments for sarcopenia could potentially hinder the delivery of effective medicines to patients at risk
Clinical relevance of contextual factors as triggers of placebo and nocebo effects in musculoskeletal pain
Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty
Short-term placebo response in trials of patients with symptomatic osteoarthritis: differences between hip and knee
Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medical products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement.
Objective: The European Society on Clinical and Economic aspects of Osteoporosis and Osteoarthritis
(ESCEO) organised a working group to evaluate the need for updating the current European guideline on
clinical investigation of drugs used in the treatment of osteoarthritis (OA).
Design: Areas of potential attention were identified and the need for modifications, update or clarification
was examined. Proposals were then developed based on literature reviews and through a
consensus process.
Results: It was agreed that the current guideline overall still reflects the current knowledge in OA,
although two possible modifications were identified. The first relates to the number and timing of
measurements required as primary endpoints during clinical trials of symptom-relieving drugs, either
drugs with rapid onset of action or slow acting drugs. The suggested modifications are intended to take
into consideration the time related clinical need and expected time response to these drugs e i.e., a more
early effect for the first category in addition to the maintenance of effect, a more continuous benefit over
the long-term for the latter e in the timing of assessments.
Secondly, values above which a benefit over placebo should be considered clinically relevant were
considered. Based on literature reviews, the most consensual values were determined for primary
endpoints of both symptom-relieving drugs (i.e., pain intensity on a visual analogue scale (VAS)) and
disease-modifying drugs (i.e., radiographic joint-space narrowing)
Recommendations for an update of the current (2010) European Regulatory Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes
peer reviewe
Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medical products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement.
Objective: The European Society on Clinical and Economic aspects of Osteoporosis and Osteoarthritis
(ESCEO) organised a working group to evaluate the need for updating the current European guideline on
clinical investigation of drugs used in the treatment of osteoarthritis (OA).
Design: Areas of potential attention were identified and the need for modifications, update or clarification
was examined. Proposals were then developed based on literature reviews and through a
consensus process.
Results: It was agreed that the current guideline overall still reflects the current knowledge in OA,
although two possible modifications were identified. The first relates to the number and timing of
measurements required as primary endpoints during clinical trials of symptom-relieving drugs, either
drugs with rapid onset of action or slow acting drugs. The suggested modifications are intended to take
into consideration the time related clinical need and expected time response to these drugs e i.e., a more
early effect for the first category in addition to the maintenance of effect, a more continuous benefit over
the long-term for the latter e in the timing of assessments.
Secondly, values above which a benefit over placebo should be considered clinically relevant were
considered. Based on literature reviews, the most consensual values were determined for primary
endpoints of both symptom-relieving drugs (i.e., pain intensity on a visual analogue scale (VAS)) and
disease-modifying drugs (i.e., radiographic joint-space narrowing)
Health economics in the field of osteoarthritis: an expert's consensus paper from the European society for clinical and economic aspects of osteoporosis and osteoarthritis
Objectives: there is an important need to evaluate therapeutic approaches for osteoarthritis (OA) in terms of cost-effectiveness as well as efficacy.Methods: the ESCEO expert working group met to discuss the epidemiological and economic evidence that justifies the increasing concern of the impact of this disease and reviewed the current state-of-the-art in health economic studies in this field.Results: OA is a debilitating disease; it is increasing in frequency and is associated with a substantial and growing burden on society, in terms of both burden of illness and cost of illness. Economic evaluations in this field are relatively rare, and those that do exist, show considerable heterogeneity of methodological approach (such as indicated population, comparator, decision context and perspective, time horizon, modeling and outcome measures used). This heterogeneity makes comparisons between studies problematic.Conclusions: better adherence to guidelines for economic evaluations is needed. There was strong support for the definition of a reference case and for what might constitute “standard optimal care” in terms of best clinical practice, for the control arms of interventional studies<br/